choroidal melanomasll-13 and should theoretically minimise the exposure of uninvolved tissues in the treatment of CCH. We present 3 cases of CCIl at the posterior pole treated with proton beam therapy at the Douglas Cyclotron, Clatterbridge. All patients received a dose of 1800 cGy (1980 cGy cobalt equivalent) in 4 fractions ( Table 1 ).
Case reports

Patient 1
A 52-year-old man presented with blurred vision and metamorphopsia in his left eye with a Snellen acuity of 6/6. A diagnosis of juxtapapillary circumscribed choroidal haemangioma was made and conservative follow-up ensued. Two years later, the patient developed a serous retinal detachment over the tumour with a drop in visual acuity to 6/18. Scatter argon laser photocoagulation was performed with poor resolution of the detachment and the visual acuity deteriorated further to 6/60. Proton beam therapy was administered 3 months after the onset of visual impairment. At 1 month after treatment the visual acuity had returned to 6/24 and continued to improve to 6/18 over the next 2 year period with complete resolution of subretinal fluid with pigmentary macular changes. However, at follow-up 32 months after irradiation visual acuity had declined to 6/60 and fundoscopy revealed a swollen optic disc with telangiectatic vessels with lipid exudates and oedema at the macula (Fig. 1) Timing of PBT after symptom onset (months) 3
Resolution of subretinal fluid after PBT (months) 32
Onset of radiation changes after PBT (months) acuity remained at hand movements after proton beam therapy and there was slow resolution of subretinal fluid.
The tumour continued to show shrinkage documented by serial ultrasound. At 1 year follow-up there was marked radiation optic neuropathy and maculopathy. At 3 year follow-up the macula was noted to be dry and atrophic.
Patient 3
32
A 39-year-old man was referred with a CCH just temporal to the fovea in his right eye. His left eye was amblyopic. Visual acuity was 6/12 and 6/24 in the right and left eyes respectively. He underwent four sessions of argon laser photocoagulation with initial resolution of fluid and improvement of the visual acuity to 6/9 (Fig.  2) . The vision deteriorated again within 6 months of stopping treatment, with extensive exudative retinal detachment and cystoid macular oedema. Six years later there was concern over progressive increase in tumour thickness. The decision was taken to treat the tumour with proton beam therapy in the hope of shrinking the tumour and preventing further extensive bullous 
Diagnosis and treatment of CCR
In the past CCH have proved a diagnostic pitfall in many cases, with the diagnosis only made histologically after the eye has been enucleated for suspected amelanotic choroidal melanoma.14 Fortunately with the routine use of fluorescein angiography and B-scan ultrasound the modern ophthalmologist should be able to distinguish a CCH with increased certainty.15,16 It is rare to clinically observe growth in CCH as in case 3Y However, even if the correct diagnosis is made in time, both the location and the natural history of these sight-threatening harmatomas make consensus in the choice and timing of treatment difficult.1 They classically occur at the posterior pole and juxtapapillary area2 and cause symptoms rapidly once subretinal fluid leakage occurs. The course of this visual deterioration may be relapsing and remitting and may lull the clinician into a false sense of security while missing the critical period for treatment when optimal visual outcome can be achieved. If unchecked, glaucoma may result from angle neovascularisation or angle closure.
Many authors recommend laser photocoagulation. Although this often results in a temporary resolution of the serous detachment, many reports have documented the re-accumulation of the sub retinal fluid and poor final visual acuity?-5 This poor outcome is reflected in patients 1 and 3. Both brachytherapi8 and external beam irradiation7,18 have shown some promise in treating CCH.
Characteristics of proton beam therapy
Charged particle irradiation was advocated as a treatment for haem angiomas in this critical region due to its attractive physical characteristics. In contrast to conventional radiotherapy with its collateral irradiation of surrounding tissues, especially at the entry site, the energy in proton beam therapy is deposited at the end of its path (Bragg peak of ionisation)12 (Fig. 3) . Because the precise depth of penetration can be controlled, the radiation can be targeted almost exclusively to the tumour volume with minimal irradiation of the ,-... Depth in phantom (mm Perspex) surrounding tissue. Accurate localisation of the tumour is achieved by the insertion of at least four radio-opaque tantalum markers sutured to the sclera at known distances from the tumour edge. These are inert and left in situ after treatment. Localisation can be further improved for these posterior lesions by choosing an appropriate fixation angle which brings the tumour closer to the entrance of the beam. Precise targeting is further achieved with bite blocks and face and head masks of mouldable plastic mesh.s Similar to conventional radiotherapy, proton therapy uses dose fractionation and multiport beam entry. Proton beam treatment has been described for both CCH and diffuse choroidal haem angioma by Zografos et al. in three cases.9,10 He observed no radiation complications except for subretinal fibrosis in one case of macular CCH. This case showed marked improvement of vision from 6/60 to 6/7.5 at 1 year follow-up.lO This favourable outcome over a short follow-up period invites comparison with the initial improvement in case 1.
Visual outcomes, tumour shrinkage and subretinal fluid resolution
The visual outcome in our 3 cases reflects the response to external radiotherapy reported by Schilling et al? (Berlin / Essen group) that the functional success of the treatment depended on the lag duration between first onset of symptoms and treatment. Patient 1, who presented early, had an initial impressive visual improvement after treatment. Both patients 2 and 3, who had symptoms and poor visual acuity of long duration, did not improve after treatment. None of our patients has yet developed the subretinal fibrosis described as being a prevalent cause of late visual deterioration? None of our patients developed neovascular glaucoma. There was no radiation-induced cataract.
All the tumours treated with proton therapy showed marked shrinkage and in patients 1 and 2 were undetectable by ultrasound after 3 years of follow-up.
Radiation doses and side-effects
The radiation doses were chosen empirically as there is little precedence in using proton beam therapy to treat CCH. There is still no consensus as to the ideal radiation dose to treat this tumour. (The dose depends on the relative biological effectiveness of the source, so direct dose comparisons between different treatment modalities are not possible.) The choice hinges on whether one is aiming merely for resolution of the sub retinal fluid or for actual shrinkage of the tumour volume. With external beam radiotherapy, the Berlin/ Essen group aimed for the former and advocated using a lower radiation dose, whereas the London groupl felt that a higher dose causing an effective decrease in tumour size decreases symptoms of metamorphopsia and prevents further recurrences. We currently prescribe a total dose of 1800-3000 cGy administered in 15-19 fractions with lens-sparing external beam radiotherapy.
Gragoudas et alY described proton treatment of choroidal melanomas within 3 mm of the fovea and/or optic nerve area showing variable changes in visual acuity, but the majority of their patients had less than 2 years of follow-up. It is interesting to speculate why these radiation changes have developed given that the dose of 1800 cGy for CCH is significantly lower than the dose of 5200 cGy for choroidal melanomas.1Y This may be attributed to the vascularity of these lesions causing increased absorption leading to radiation changes. Also the dose fractionation may not be adequate compared with conventional radiotherapy that is administered in 20 or more fractions.
Current choice of CCH treatment
Since its discovery by Wilson in 1946, proton therapy has moved out of the physics research laboratory to costly purpose-built clinical facilities to treat a very specific subgroup of tumours?O. 21 The cost-benefit ratio is constantly being evaluated. In the field of ophthalmology there have been recent publications 19 questioning the justification of treating choroidal melanomas with proton beam therapy rather than other modes of treatment. 21 In our experience, proton beam therapy for CCH causes effective tumour shrinkage but does not appear to be less likely to cause radiation-induced damage than does external beam lens-sparing radiotherapy or brachytherapy. Given the large cost difference between proton beam therapy and the other available treatments, the treatment of choice for CCH in the current climate of an increasingly cost-conscious health service appears to be obvious.
